The conversation is about whether the phase 2 results for pyrilutamide, a potential hair loss treatment, were presented at a dermatology convention and inquiries about the completion of phase 3 trials. Specific treatments mentioned include pyrilutamide.
The conversation discusses skepticism about a new hair loss treatment called project K, which claims to replicate a chemical from UCLA research but is suspected to be a scam. The original poster plans to continue using oral minoxidil, finasteride, and dutasteride, along with microneedling, for hair regrowth.
The conversation is about whether stemoxydine can shorten the dormant phase after a hair transplant, known as the ugly duckling phase. There is skepticism about whether it actually works as claimed.
Actifolic's RU58841 and Pyri products are perceived as ineffective, with users reporting no side effects or improvements, suggesting possible quality issues. Users recommend alternative sources and emphasize the importance of timing when using RU58841 with Minoxidil.
The conversation is about when the phase 3 results for pyrilutamide, a potential hair loss treatment, will be released. There was a letter about the study a month ago, but the actual results were not included.
A dermatologist refused to prescribe finasteride due to concerns about recent research linking it to male breast cancer, suggesting a topical alternative with minoxidil instead. The user is advised to seek a second opinion, as the evidence for such risks is inconclusive and the dermatologist's reasoning seems questionable.
The conversation discusses the complexity of hair loss causes, suggesting that DHT sensitivity alone doesn't fully explain it. Treatments mentioned include finasteride and dutasteride.
The conversation is about a user trying to fund lab testing for RU58841 to verify its legitimacy, as there are doubts about its effectiveness. Some users express skepticism about RU58841, suggesting alternatives like KX-826.
Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.
A satirical discussion on using minoxidil and finasteride in unconventional ways, including mixing them into drinks and other humorous methods. The conversation also touches on the potential health risks of minoxidil.
User tried microneedling with min and fin for hair loss, experienced inflamed scalp and dandruff. Recommends proper disinfection of microneedler to avoid issues.
A user who is using Pyrilutamide, Finasteride, and a homemade topical solution to treat their hair loss. Replies mentioned the potential of Pyrilutamide being a "cure" for hair loss and a reminder that results may not be credited solely to it.
A user bought Kirkland Minoxidil from a TikTok shop and sought confirmation of its authenticity through a bleach test, which some users warned could be dangerous. Many participants advised against buying from TikTok due to the risk of fakes, suggesting alternatives like buying from Costco or reputable online pharmacies.
The conversation humorously discusses hair loss treatments, mentioning spironolactone and cyproterone acetate. It reflects a sense of frustration and satire about the effectiveness of these treatments.
Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.
The conversation is about a user expressing concerns over the safety of a new drug called Pyrilutamide (also known as KX-826) for hair loss. The user will only trust the drug if it's permitted by EU regulations and sold by a reputable company.
The conversation is about a product called Serioxyl, which was expected to contain stemoxydine. It clarifies that Diethyl lutidinate is another name for stemoxydine.
Oral minoxidil is temporarily unavailable in the USA due to import laws, prompting consideration of topical minoxidil as an alternative. Tariffs and political policies affect the availability and cost of hair loss treatments.
Dutasteride at 0.5mg may have fewer sexual side effects than expected, with many side effects attributed to psychological factors (nocebo effect). The placebo group experienced more side effects, suggesting fear and anxiety might contribute to perceived side effects.
A user humorously discusses their 10-month-old's hair loss, suggesting treatments like microneedling, minoxidil, finasteride, and RU58841. Replies include various satirical and exaggerated suggestions, emphasizing the post's satirical nature.
The conversation is about seeking updates on the hair loss treatment RCH-01, specifically its next phase and any news from Shiseido. The user recalls someone being in contact with a researcher or company representative.
Blocking DHT is not a cure for hair loss; instead, altering how scalp follicles respond to DHT might be more effective. Current treatments like topical finasteride and minoxidil are temporary solutions, and future approaches may involve gene therapy and bioengineering to change follicle behavior.
The conversation is about someone seeking information on long-term users of CB-03-01 for hair loss, having experienced negative side effects from finasteride and facing rapid hair thinning.
The conversation is about the release of Phase 3 trial results for pyrilutamide in China for treating hair loss. The user is inquiring if the actual results have been posted, noting that a recent release did not contain them.
Missing one day of finasteride is humorously discussed, with suggestions to use additional treatments like dutasteride, RU58841, minoxidil, and microneedling. Some users jokingly suggest shaving the head or traveling for hair restoration.
The conversation is about making a topical solution from clascoterone powder, with references to using a RU58841 mixing guide for guidance. Concerns about product authenticity and bulk purchase requirements are also discussed.
Discussion on hair loss treatments, focusing on pp405, with skepticism about its effectiveness and concerns about its association with the cosmetic industry. Users also mention treatments like Minoxidil and Finasteride.
SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.
A user shares optimism about combating male pattern baldness using oral and topical minoxidil, highlighting the advancements in treatments available today. Another user agrees, noting that early treatment can yield good results, and mentions the availability of affordable hair transplants.